SCHEMBL3337463

SCHEMBL3337463

CN(C)c1cc(Nc2nc(Cl)ncc2Cl)n[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PLK4 O00444 2/20 0.41
PAK4 O96013 2/20 0.41
NTRK1 P04629 6/20 0.41
JAK2 O60674 4/20 0.41
IGF1R P08069 4/20 0.41
AURKA O14965 2/20 0.41
FGFR1 P11362 2/20 0.41
JAK3 P52333 2/20 0.41
STK10 O94804 1/20 0.41
RET P07949 1/20 0.41
FER P16591 1/20 0.41
CSNK2A2 P19784 1/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
FLT3 P36888 1/20 0.41
STAT3 P40763 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3342973 0.88 KMT2A (0.42) MEN1HTTKMT2AHSD17B10PLK4
SCHEMBL218642 0.81 MEN1 (0.62) MEN1HTTKMT2AHSD17B10PLK4
SCHEMBL2120951 0.78 NTRK1 (0.58) MEN1HTTKMT2AHSD17B10PLK4
SCHEMBL1770945 0.78 FGFR1 (0.46) MEN1HTTKMT2AHSD17B10PLK4
SCHEMBL3341156 0.78 IGF1R (0.43) MEN1HTTKMT2AHSD17B10PLK4
SCHEMBL217676 0.78 JAK2 (0.42) MEN1HTTKMT2AHSD17B10PLK4
SCHEMBL4041620 0.78 NTRK1 (0.46) MEN1HTTKMT2AHSD17B10PLK4
SCHEMBL3236981 0.76 ALDH1A1 (0.49) MEN1KMT2APAK4NTRK1IGF1R
SCHEMBL4040276 0.76 FGFR1 (0.46) MEN1HTTKMT2AHSD17B10PLK4
SCHEMBL4073779 0.76 IGF1R (0.42) MEN1HTTKMT2AHSD17B10PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1945631-B1 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2012-08-08 EP disclosed
US-20100160325-A1 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2010-06-24 US disclosed
US-20100152219-A1 PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTRAZENECA R&D (SE) 2010-06-17 US disclosed
EP-1686999-B1 PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTRAZENECA AB (SE) 2009-07-01 EP disclosed
US-20080287475-A1 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer ASTRAZENECA AB (SE) 2008-11-20 US disclosed
US-20070142413-A1 Pyrazole derivatives as inhibitors of receptor tyrosone kinases ASTRAZENECA AB (SE) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152219-A1 PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES LTK, ERBB2, ERBB3 MEN1 4122/4885HTT 4722/4885KMT2A 3290/4885
US-20080287475-A1 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer ABL1, FLT3, ERBB2 MEN1 3874/4885HTT 4785/4885KMT2A 1276/4885
US-20100160325-A1 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER ABL1, FLT3, ERBB2 MEN1 3874/4885HTT 4785/4885KMT2A 1276/4885
US-20070142413-A1 Pyrazole derivatives as inhibitors of receptor tyrosone kinases PRKDC, MUSK, LTK MEN1 3958/4885HTT 4744/4885KMT2A 3119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.